The Galien Forum USA 2019

MedStartUp
PANEL

Chair
Sergio Rossi
Managing Director & Partner
Boston Consulting Group

Panelists
Abel Archundia, MBA
Global Head of IT & Digital Transformation
Bayer Pharmaceuticals

Ülo Palm, MD, PhD, MBA
Senior Vice-President, Digital Sciences
Allergan

Satty Chandrashekhar
Managing Director and Partner
Boston Consulting Group

Joanna Wolkowski, MBA
Vice-President, Portfolio & Decision Analysis
Pfizer

Panel Intro

Brought to you by BCG

BCG logo

Prioritization and acceleration of biopharma asset performance through advanced analytics


Sergio RossiChair
Sergio Rossi, MBA
Managing Director & Partner
Boston Consulting Group

He previously was based in Europe and he is core member of HC practice within BCG, covering corporate strategy and commercial model innovation via leveraging Advanced Analytics.

Sergio has worked across several topics  strategy, operations, commercial models, GTM and recently deep dived on how data and analytics can accelerate and improve current operating models and what additional business models can be enabled.

Michael holds a M.Sc. degree in Aerospace Engineering from Polytechnic School of Torino and conduct his research at Princeton University.


Abel Archundia

Abel Archundia, MBA
Global Head of IT & Digital Transformation
Bayer Pharmaceuticals

Abel joined Bayer in 2017 and is currently the Global Head of IT at Bayer   Pharma and member of the Bayer Group IT board. He is driving the  organization’s digital transformation and is passionate about  technology and   data and the beneficial impact they have to sustainably improve and transform   patient health.


Ülo Palm, MD, PhD, MBA
Senior Vice-President, Digital Sciences
Allergan

Before taking over this newly created role, Dr. Palm led the Global Drug Development Operations organization at Allergan. Prior to Allergan, he was the SVP Clinical Operations & Biometrics and Therapeutic Area Head Respiratory Clinical Development with Forest Labs. Before joining Forest, Dr. Palm held the positions of Global Head Laboratory & Preclinical Quality Assurance and  Global Head Clinical Operations Oncology with Novartis Pharmaceuticals. Prior to Novartis, Dr. Palm worked at Schering-Plough and Bayer in different operational and medical drug development functions. He has a total of 30 years of experience in the pharmaceutical industry.

Dr. Palm earned his M.D. (Internal Medicine, Neurology, Surgery) from the University of Berlin, Germany, where he also received a postgraduate research training as a medical scientist. He completed his research training with a PhD. His scientific work focused on kidney and electrolyte physiology, biological rhythms and their mathematical analysis, as well as catheter related infections. He is author and co-author of a number of scientific articles in international journals.

He earned his MBA degree with a major in Information Technology/Computer Sciences from the AKAD University for Applied Science in Rendsburg, Germany.
Dr. Palm is a Senior Member of the American Society for Quality (ASQ) and a certified Manager of Quality and Organizational Excellence (ASQ-CMQ/OE). His work at the ASQ includes initiating and co-authoring the ASQ report on “Best Quality Practices For Biomedical Research In Drug Development”.

He has been a member and past chair of the TransCelerate BioPharma Oversight Committee and several sub-committees since 2013. He was appointed Corporate Secretary of TransCelerate BioPharma in 2017.

Dr. Palm’s overall vision is to expedite the development of new drugs by linking top medical science to operational excellence and 21st century technology.


Satty

Satty Chandrashekhar
Managing Director and Partner
Boston Consulting Group

As a leader in BCG GAMMA, Satty helps health care organizations conceive and create differentiated outcomes with advanced analytics and AI.

Satty has worked for a number of biopharma, provider, and payer clients on topics across health data and analytics strategy, technology enablement, operating models and partnerships.

Previously Satty was Managing Director at another global professional services firm. Satty holds a Bachelors in Electronics and Communication Engineering (with distinction) from the Birla Institute of Technology, Ranchi, India.


Joanna WolkowskiJoanna Wolkowski, MBA
Vice-President, Portfolio and Decision Analysis
Pfizer

Her group is responsible for driving rigorous analyses and generating competitive insights to enable R&D investment decisions which maximize pipeline value and enable Pfizer’s long-term strategy. In addition to building and maintaining robust economic valuations for 100+ R&D projects, PDA oversees overall portfolio health and sustainability for Pfizer’s senior-most leaders.

Formerly, Joanna was a Principal at the Boston Consulting Group in the firm’s Health Care Practice Area. Her experience focused on corporate and commercial strategy within the pharmaceutical industry, driving strategic recommendations across therapeutic areas at the highest levels of client organizations. Earlier in her career, Joanna worked for six years with Pfizer as a Discovery Chemist, Pharmaceutical Sales Representative, and Associate within the Strategic Management Group. She also worked with Sierra Nevada Brewing Company in their Sales and Marketing Division.

Joanna earned a BA in Chemistry from Middlebury College, an MS in Chemistry from Yale University, and an MBA in Health Care Management and Strategic Management from the Wharton School of the University of Pennsylvania. In addition to being a sports enthusiast and avid runner, golfer, and skier, she enjoys boating and brewing her own beer.